-
公开(公告)号：EP1317270A1
公开(公告)日：2003-06-11
申请号：EP01969689.7
申请日：2001-08-31
发明人： DI SALLE, Enrico , PISCITELLI, Gabriella , MASSIMINI, Giorgio , PURANDARE, Dinesh , MARTINI, Alessandro , MUGGETTI, Lorena
IPC分类号： A61K31/5685 , A61P35/00
CPC分类号： A61K45/06 , A61K31/5685 , A61K2300/00
摘要： The present invention concerns the use of aromatase inhibitor exemestane, either alone or in combination with other therapeutic agents, in the chemoprevention of estrogen dependent cancer in mammals, including humans, at increased risk of the disease.
-
公开(公告)号：EP1282402A1
公开(公告)日：2003-02-12
申请号：EP01945040.2
申请日：2001-04-25
CPC分类号： A61K47/183 , A61K9/0019 , A61K9/10
摘要： A pharmaceutical aqueous suspension formulation for parenteral administration having substantially stabilized pH, comprising a biologically active compound and a pH controlling effective concentration of L-Methionine. Preferably, the biologically active compound is a steroidal compound, for instance exemestane, medroxyprogesterone acetate and estradiol cypionate or a combination of medroxyprogesterone acetate and estradiol cypionate.
-
公开(公告)号：EP1282402B1
公开(公告)日：2005-12-21
申请号：EP01945040.2
申请日：2001-04-25
CPC分类号： A61K47/183 , A61K9/0019 , A61K9/10
摘要： A pharmaceutical aqueous suspension formulation for parenteral administration having substantially stabilized pH, comprising a biologically active compound and a pH controlling effective concentration of L-Methionine. Preferably, the biologically active compound is a steroidal compound, for instance exemestane, medroxyprogesterone acetate and estradiol cypionate or a combination of medroxyprogesterone acetate and estradiol cypionate.
-
公开(公告)号：EP1223936A1
公开(公告)日：2002-07-24
申请号：EP00966102.6
申请日：2000-10-02
CPC分类号： A61K31/4745 , A61K9/4866
摘要： The present invention relates to a semi-solid filling medium which comprises a camptothecin derivative; a pharmaceutically acceptable carrier matrix which is a polyglycolized glyceride; and an effective thickening-reducing and stabilising-promoting amount of one or more pharmaceutically acceptable excipients.
-
5.发明公开FORMULATIONS FOR PARENTERAL USE OF ESTRAMUSTINE PHOSPHATE AND SULFOALKYL ETHER CYCLODEXTRINS 审中-公开适用非肠道药物制剂含磷酸雌莫司汀和SULPHOALKYLCYCLODEXTRINE
公开(公告)号：EP1212041A1
公开(公告)日：2002-06-12
申请号：EP00958398.0
申请日：2000-08-03
IPC分类号： A61K9/08 , A61K47/40 , A61K31/565 , A61P35/00
CPC分类号： A61K9/0019 , A61K31/661 , A61K45/06 , A61K47/40 , A61K2300/00
摘要： A pharmaceutical formulation which comprises a parenterally acceptable carrier or diluent, estramustine phosphate and a sulfoalkyl ether cyclodextrin. The formulation can be administered according to a combined chemotherapy regimen in association with one or more chemotherapeutic agents. The formulation also enables estramustine phosphate to be administered with no side effects at the site of injection.
-
公开(公告)号：EP1282401A2
公开(公告)日：2003-02-12
申请号：EP01936274.8
申请日：2001-04-25
CPC分类号： A61K9/0019 , A61K9/10 , A61K47/32
摘要： A pharmaceutical aqueous suspension formulation for parenteral administration having substantially stabilized pH, comprising a biologically active compound and a pH controlling effective concentration of a polyvinylpyrrolidone compound. Preferably the biologically active compound is a steroidal compound, for instance, exemestane, medroxyprogesterone acetate or estradiol cypionate or a combination of medroxyprogesterone acetate and estradiol cypionate.
-
公开(公告)号：EP1453517B1
公开(公告)日：2006-02-08
申请号：EP02787779.4
申请日：2002-11-22
IPC分类号： A61K31/519 , A61K47/12 , A61P35/00
CPC分类号： A61K31/555 , A61K9/0019 , A61K31/519 , A61K47/12
摘要： The present invention relates to novel stable solution formulations comprising oxaliplatin, an effective stabilizing amount of lactic acid and/or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. A method for manufacturing such formulations ready for administration and their use in the antitumor therapy are also within the scope of the invention.
-
公开(公告)号：EP1515959A1
公开(公告)日：2005-03-23
申请号：EP03725195.6
申请日：2003-06-04
IPC分类号： C07D265/30 , A61K31/5375 , A61P25/24
CPC分类号： A61K31/5375 , C07D265/30
摘要： The present invention relates to novel crystalline, water-soluble salts of the 2S,3S enantiomer of reboxetine, which are the fumarate and succinate salts thereof, to a process for their preparation, to their utility in therapy and to pharmaceutical compositions containing them.
-
9.发明公开
公开(公告)号：EP1206266A2
公开(公告)日：2002-05-22
申请号：EP00949471.7
申请日：2000-08-03
IPC分类号： A61K31/565 , A61K31/66 , A61K9/08 , A61K47/42 , A61P35/00
CPC分类号： A61K31/661 , A61K9/0019 , A61K31/335 , A61K31/40 , A61K31/47 , A61K31/475 , A61K31/555 , A61K31/565 , A61K31/66 , A61K31/70 , A61K33/00 , A61K38/38 , A61K47/42 , A61K2300/00
摘要： A pharmaceutical formulation which comprises a parenterally acceptable carrier or a diluent and estramustine phosphate in admixture with human albumin, wherein the weight ratio of estramustine phosphate to human albumin is from about 1:5 to about 1:0.3. The formulation can be administered according to a combined chemotherapy regimen in association with one or more chemotherapeutic agents. The formulation also enables estramustine phosphate to be administered with no side effects at the side of injection.
-
公开(公告)号：EP1409502A2
公开(公告)日：2004-04-21
申请号：EP02751122.9
申请日：2002-07-08
发明人： MARTINI, Alessandro , ZAMPIERI, Massimo , FUMAGALLI, Paolo , GIORDANO, Ferdinando , BETTINI, Ruggero
IPC分类号： C07H15/252 , A61K31/704 , A61P35/00
CPC分类号： C07H15/252
摘要： There are provided a method for making highly purified crystals of anthracycline derivatives, and a new crystalline form of 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methansulfonyl daunorubicin, useful in the treatment of tumors.
-
-
-
-
-
-
-
-
-
搜索结果
17 条记录 (耗时 0.013 秒)
